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Metabolic syndrome in clinical practice
We read with interest Fisman and Tenenbaum 
review [1] that discuss the predictive value of 
the metabolic syndrome (MetS) in terms of car-
diovascular (CV) morbidity and mortality, thus 
highlighting its importance as an additional tool 
to estimate individual CV risk. A few comments 
may be of interest.
Apart from non-alcoholic fatty liver disease 
(NAFLD) and hyperuricemia [2] already mentioned 
in the review, MetS has also been linked to chronic 
kidney disease (CKD) [3] and peripheral artery 
disease (PAD) [4]. We have previously shown that 
MetS patients without diabetes had similar vascu-
lar disease prevalence (including coronary heart 
disease, stroke and PAD as those with diabetes but 
without MetS (24.1% vs. 25.4%, respectively) [5].
Statins play an important role in the treatment 
of MetS [6]. We have previously reported that 
statins, either alone (in the GREek Atorvastatin 
and Coronary heart disease Evaluation [GREACE] 
Study) or as a part of a multifactorial intervention 
(in Assessing The Treatment Effect in Metabo- 
lic syndrome without Perceptible diabeTes 
[ATTEMPT] study), may improve not only CV risk 
but also serum uric levels, kidney and renal function 
[7–10]; these beneficial effects were more pro-
minent in CKD and NAFLD patients. Therefore, 
clinicians should keep in mind that these disease 
states related to MetS might help to intensify and 
tailor treatment to maximize clinical benefit.
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